GlaxoSmithKline Pharmaceuticals Limited has received a below mentioned orders. Final Order from the ACIT Cir 7(1)(1) with the Demand Liability of INR 194.5 million. The relevant details to be disclosed is as under: Name of the authority: DCIT issued the Assessment Order (under faceless Assessment) u/s 143(3) r.w. Section 144C (3) for the AY 2022-2023.

Nature and details of the action(s) taken, initiated or order(s) passed: Demand raised for INR 72.2 million after disallowing a few expenses for the GSK AY: 2022-2023. Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority: 22 March, 2024; Impact on financial, operation, or other activities of the listed entity, quantifiable in monetary terms to the extent possible: At present, there is no impact on GSK as this is a Legacy issue for GSK under litigation for the past years. GSK will be going to file a further appeal at the 1st appellate authority.

challenging the Assessing Officer Order. Company has received an Order dated 20th March 2024 from Haryana GST authorities, disallowing certain GST credits in Haryana State. The relevant details to be is disclosed is as under: Name of the authority: Assistant Commissioner of GST, 26/615, Manav Chowk, Ambala; Nature and details of the action(s) taken, initiated or order(s) Passed: Order dated 20th March 2024 passed under Section 74 of CGST Act, 2017 for Tax of INR 46,61,258 along with applicable interest and Penalty of INR 46,52,194, aggregating to demand of INR 93,22,516 for Fiscal year 18-19 in Haryana State.

Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority: 21 March 2024. Details of violation(s) /contravention(s) committed or alleged to be committed: The officer has disallowed certain GST credit and raised GST demand for fiscal year 2018-19 on account of difference in GST credit mismatch between company?s GST returns and details reported by vendors in their GST returns. Company has received an Order dated 14 March 2024 from Tamil Nadu GST and Central Excise authorities, disallowing certain GST credits in Tamil Nadu State.

The relevant details to be is disclosed is as under: Name of the authority: Deputy Commissioner of GST and Central Excise, Poonamallee Division ­ Chennai Outer Commissionerate. Nature and details of the action(s) taken, initiated or order(s) Passed: Order dated 4 March 2024 passed under Section 73 of CGST Act, 2017 for Tax of INR 6,90,266 along with applicable interest and Penalty of INR 89,620, aggregating to demand of INR 7,79,886 for FY18-19 in Tamil Nadu State. Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority: 14 March 2024.

Details of violation(s) /contravention(s) committed or alleged to be committed: The officer has disallowed certain GST credit and raised GST demand for Fiscal Year 2018-19 on account of difference in GST credit mismatch between Company's GST returns and details reported by vendors in their GST returns. Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible: No impact on GSK. The Company believes that the said demand is not maintainable and will be filing an Appeal against the said Order.